- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterSaturday, May 31, 2008
OncoLink reporters provide in-depth coverage of scientific presentations from the 44th Annual ASCO Meeting.
|
A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07
Presenter: N. WolmarkPresenter's Affiliation: NSABPType of Session: ScientificBackground Prior studies have demonstrated that postoperative adjuvant chemotherapy for patients with high-risk colon cancer improves patient outcome. The standard of... |
|
|
A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07
A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 Previous studies have shown a benefit to adding oxaliplatin to the standard 5-FU and leucovorin in adjuvant... |
|
|
Bortezomib/dexamethasone versus VAD as Induction Prior to Autologous Stem Cell Transplant (ASCT) in Previously Untreated Multiple Myeloma (MM): Updated Data from IFM 2005/01 Trial
Presenter: Harousseau J.L.Presenter's Affiliation: Hoteldieu Hospital, Nantes, FranceType of Session: ScientificBackground Multiple Myeloma (MM) remains an incurable condition, with a median survival of 48-68 months. Autologous stem cell... |
|
|
Bortezomib/dexamethasone versus VAD as Induction Prior to Autologous Stem Cell Transplant (ASCT) in Previously Untreated Multiple Myeloma (MM): Updated Data from IFM 2005/01 Trial
Bortezomib/dexamethasone versus VAD as Induction Prior to Autologous Stem Cell Transplant (ASCT) in Previously Untreated Multiple Myeloma (MM): Updated Data from IFM 2005/01 Trial The use of autologous stem cell transplant in treating multiple... |
|
|
BRCA1 mRNA expression in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy
Presenter: A. FontPresenter's Affiliation: ICO Hospital Germans Trias i Pujol, Badalona, Spain; Univerdidad Complutense, Madrid, SpainType of Session: ScientificBackground In the form of meta-analysis, an overall survival benefit has been... |
|
|
BRCA1 mRNA expression in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy
BRCA1 mRNA expression in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy Improved overall survival has been demonstrated with the use of cisplatin-based chemotherapy given prior to radical cystectomy in patients... |
|
|
Deforolimus Trial 106-A Phase I Trial Evaluating 7 Regimes of Oral Deforolimus (AP23573, MK-8669)
Presenter: Mita M.M.Presenter's Affiliation: University of Texas Health and Science Center, San AntonioType of Session: ScientificBackground Prior studies have validated mTOR as a target in cancer therapy. mTOR is a downstream... |
|
|
Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double blind NCCTG trial N04C7
Presenter: D. A. NikcevichPresenter's Affiliation: Mayo Clinic/ NCCTGType of Session: ScientificBackground The addition of oxaliplatin to 5FU and leucovorin chemotherapy has been shown to be effective in the adjuvant setting for colon cancer in... |
|
|
Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double blind NCCTG trial N04C7
Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double blind NCCTG trial N04C7 The addition of oxaliplatin to the... |
|
|
Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity
Presenter: S.I.Ou Presenter's Affiliation: Chao Family Comprehensive Cancer Center, University of California, Orange, CA; University of California Irvine, Irvine, CA Type of Session: Scientific Background Non-small cell lung cancer (NSCLC)... |
|
|
Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity
Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity Non-small cell lung cancer (NSCLC) remains the number one cause of... |
|
|
Evaluation of chromosome 17 (Chr-17) polysomy in Her2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib
Presenter: R. B. LivingstonPresenter's Affiliation: Arizona Cancer Center, Tuscon, AZType of Session: ScientificBackground Lapatinib is an oral small-molecule dual tyrosine kinase (TK) inhibitor which targets Her2 receptors and is being... |
|
|
Evaluation of chromosome 17 (Chr-17) polysomy in Her2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib
Evaluation of chromosome 17 (Chr-17) polysomy in Her2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib Researchers believe that having multiple copies of a cromosome (i.e. 3... |
|
|
Initial Safety Report of NSABP C-08, a Randomized Phase III Study of Modified 5-Flurouracil (5-FU/leucovorin (LCV) and oxalliplatin (OX) (mFOLFOX6) with or without Bevacizumab (bev) in the Adjuvant Treatment of Patients with Stage II/III Colon Cancer
Presenter: Allegra, C.J.Presenter's Affiliation: University of FloridaType of Session: ScientificBackground There is a rationale for combining antiangiogenic agents, such as bevacizumab, with cytotoxic chemotherapy, such as mFOLFOX6, in the... |
|
|
Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONCEPT trial
Presenter: A. Grothey Presenter's Affiliation: Mayo Clinic Type of Session: Scientific Background Oxaliplatin is widely used as a 1st line treatment for metastatic colorectal cancer (mCRC). The addition of Bevacizumab has also been shown to... |
|
|
Long-term outcomes among survivors of childhood central nervous system tumors: A report from the childhood cancer survivor study
Presenter: G. T. ArmstrongPresenter's Affiliation: St. Jude Children's Research Hospital, Memphis, TNType of Session: ScientificBackground Over 270,000 childhood cancer survivors reside in the United States, and this number is expected to grow... |
|
|
RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase III study
Presenter: R.J. MotzerPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, New York, NYType of Session: ScientificBackground Treatment of metastatic renal cell carcinoma (RCC) has changed dramatically over the past several years... |
|
|
RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase III study
RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase III study RAD001 (Everolimus) is an oral targeted therapy medication... |
|
|
Randomized Phase III Study of Capecitabine, Oxaliplatin, and Bevacizumab with or without Cetuximab in Advanced Colorectal Cancer (ACC), the CAIRO2 Study of the Dutch Colorectal Cancer Group (DCCG)
Presenter: Punt C.J.Presenter's Affiliation: UMC St Radboud, Nijmegen, NetherlandsType of Session: ScientificBackground Prior studies have found an overall survival benefit in patients with advanced colorectal cancers (ACC) treated with... |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
